PepGen Stock (NASDAQ:PEPG)

Forecast Ownership Financials Chart

Previous Close

$2.10

52W Range

$1.01 - $7.80

50D Avg

$1.76

200D Avg

$3.96

Market Cap

$133.50M

Avg Vol (3M)

$881.17K

Beta

1.88

Div Yield

PEPG Company Profile

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

May 06, 2022

Website

PEPG Performance

PEPG Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	-	$-97.74M	$-84.77M
Net Income	$-89.66M	$-89.98M	$-78.63M
EBITDA	-	$-89.09M	$-83.58M
Basic EPS	$-2.12	$-2.85	$-3.30
Diluted EPS	$-2.12	$-2.85	$-3.30

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q4 23Mar 06, 24 | 4:30 PM

Q4 22Mar 23, 23 | 4:30 PM

Peer Comparison

Ticker	Company
CRBP	Corbus Pharmaceuticals Holdings, Inc.
MOLN	Molecular Partners AG
ALEC	Alector, Inc.
CRDF	Cardiff Oncology, Inc.
NKTX	Nkarta, Inc.
FATE	Fate Therapeutics, Inc.
ELTX	Elicio Therapeutics, Inc.
SAVA	Cassava Sciences, Inc.